Edition:
United States

Apollo Endosurgery Inc (APEN.OQ)

APEN.OQ on NASDAQ Stock Exchange Global Market

3.98USD
12 Dec 2017
Change (% chg)

$-0.19 (-4.56%)
Prev Close
$4.17
Open
$4.25
Day's High
$4.25
Day's Low
$3.95
Volume
21,231
Avg. Vol
36,557
52-wk High
$21.86
52-wk Low
$3.60

Chart for

About

Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company's device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80... (more)

Overall

Beta: 0.49
Market Cap(Mil.): $72.79
Shares Outstanding(Mil.): 17.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 57.15 15.71
EPS (TTM): -- -- --
ROI: -- 13.34 31.93
ROE: -- 19.96 16.16

BRIEF-Apollo Endosurgery Inc Files For Stock Shelf Of Upto $50 Million - SEC Filing ‍​

* APOLLO ENDOSURGERY INC FILES FOR STOCK SHELF OF UPTO $50 MILLION - SEC FILING ‍​ Source text (http://bit.ly/2AONduG) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-Apollo Endosurgery Receives FDA Clearance For Overstitch Sx Endoscopic Suturing System

* APOLLO ENDOSURGERY RECEIVES FDA CLEARANCE FOR OVERSTITCH™ SX ENDOSCOPIC SUTURING SYSTEM

Nov 27 2017

BRIEF-David Pacitti joins Apollo Endosurgery board of directors

* David C. Pacitti joins Apollo Endosurgery board of directors

Nov 16 2017

BRIEF-Apollo Endosurgery reports qtrly loss per share $‍0.32​

* Apollo Endosurgery Inc - qtrly loss per share $‍0.32​ Source text for Eikon: Further company coverage:

Oct 26 2017

BRIEF-Apollo endosurgery announces CE mark approval for the Orbera365™ managed weight loss system,

* Apollo Endosurgery announces CE mark approval for the Orbera365™ managed weight loss system, expanding the indwell period from 6 months to 12 months with the gastric balloon category leader

Aug 30 2017

BRIEF-Stonepine Capital Management Llc reports 13.7 percent passive stake in Apollo Endosurgery Inc

* Stonepine Capital Management Llc reports 13.7 percent passive stake in Apollo Endosurgery Inc as of August 11, 2017 - SEC filing‍​ Source text: (http://bit.ly/2xbQJty) Further company coverage:

Aug 18 2017

BRIEF-Novo Holdings A/S reports 3.9 pct stake in Apollo Endosurgery as on Aug 14

* Novo Holdings A/S reports 3.9 percent stake in Apollo Endosurgery Inc as on August 14, 2017 - SEC filing‍​

Aug 16 2017

BRIEF-Apollo Endosurgery Q2 revenue $17.1 mln

* Apollo Endosurgery - total endo-bariatric revenues were $9.5 million for three months ended june 30, 2017, an increase of 13.0% compared to q2 of 2016

Aug 01 2017

BRIEF-Apollo Endosurgery files amended S-1 registration statement

* Files amended S-1 registration statement, sees offering of 3.5 million shares of its common stock - SEC filing

Jul 12 2017

BRIEF-Apollo Endosurgery files for stock shelf offering of ‍​up to $17.3 mln

* Apollo Endosurgery inc files for stock shelf offering of ‍​up to $17.3 million - sec filing Source text for Eikon: Further company coverage:

Jun 14 2017

Earnings vs. Estimates